A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (NCT05307705)
A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic of Scottsdale — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (50 Sites)
Showing the first 25 of 50 sites.
- Mayo Clinic of Scottsdale — Scottsdale, Arizona
- UCLA Medical Center — Los Angeles, California
- UCSF Medical Center at Mission Bay — San Francisco, California
- Stanford University Hospital — Stanford, California
- Mayo Clinic — Jacksonville, Florida
- Winship Cancer Center Emory University — Atlanta, Georgia
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- Washington University Medical School — St Louis, Missouri
- Memorial Sloan Kettering Cancer Center — New York, New York
- Wilmot Cancer Institute — Rochester, New York
- Tennessee Oncology PLLC — Nashville, Tennessee
- Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- UT Southwestern Medical Center — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- South Texas Accelerated Research Therapeutics (START) — San Antonio, Texas
- Cancer Research SA — Adelaide,
- Peter Maccallum Cancer Institute Erb — East Melbourne,
- St Vincent's Hospital — Sydney,
- Institut Jules Bordet — Anderlecht,
- Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg — Leuven,
- Princess Margaret Hospital (Hong Kong) — Toronto,
- BC Cancer Vancouver — Vancouver,
- Beijing Cancer hospital — Beijing,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: ClinicalTrials.gov@lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.